Brief: Cyclo Therapeutics Receives IND Clearance From U.S. FDA To Advance Its Phase 2 Study Of Trappsol® Cyclo™
06/12/2021 14:37
Dec 6 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS RECEIVES IND CLEARANCE FROM THE U.S. FDA TO ADVANCE ITS
PHASE
2 STUDY OF TRAPPSOL® CYCLO™ FOR THE TREATMENT OF ALZHEIMER’S DISEASE
Source text for Eikon: ID:nBw2CmXTra
Further company coverage: CYTH.O
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug